Skip to main content
ACB
NASDAQ Life Sciences

Aurora Cannabis Finalizes $100M At-The-Market Equity Program Agreement

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
8
Price
$3.79
Mkt Cap
$212.639M
52W Low
$3.44
52W High
$6.91
Market data snapshot near publication time

summarizeSummary

Aurora Cannabis has finalized the definitive sales agreement for its previously announced At-The-Market (ATM) equity program. This agreement allows the company to raise up to $100 million through the sale of common shares, which represents a substantial potential dilution of approximately 47% of the company's current market capitalization. While providing crucial capital flexibility, the significant potential dilution could exert downward pressure on the stock price. Investors should monitor the pace and pricing of share sales under this program.


check_boxKey Events

  • Finalizes $100 Million ATM Program

    Aurora Cannabis has entered into a definitive sales agreement with TD Securities (USA) LLC for an At-The-Market (ATM) equity program, formalizing the $100 million program announced earlier today.

  • Significant Potential Dilution

    The program allows for the sale of up to $100 million in common shares, which represents a substantial potential dilution of approximately 47% relative to the company's current market capitalization.

  • Agent Compensation

    TD Securities (USA) LLC will receive a commission of 2.0% of the gross proceeds from the sale of shares under the ATM program.


auto_awesomeAnalysis

Aurora Cannabis has finalized the definitive sales agreement for its previously announced At-The-Market (ATM) equity program. This agreement allows the company to raise up to $100 million through the sale of common shares, which represents a substantial potential dilution of approximately 47% of the company's current market capitalization. While providing crucial capital flexibility, the significant potential dilution could exert downward pressure on the stock price. Investors should monitor the pace and pricing of share sales under this program.

この提出時点で、ACBは$3.79で取引されており、市場はNASDAQ、セクターはLife Sciences、時価総額は約$2.1億でした。 52週の取引レンジは$3.44から$6.91でした。 この提出書類はネガティブの市場センチメント、重要度スコア8/10と評価されました。

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ACB - Latest Insights

ACB
Apr 28, 2026, 8:15 AM EDT
Filing Type: 6-K
Importance Score:
7
ACB
Apr 15, 2026, 7:21 AM EDT
Filing Type: 6-K
Importance Score:
8
ACB
Feb 12, 2026, 4:26 PM EST
Filing Type: 6-K
Importance Score:
9
ACB
Feb 04, 2026, 4:44 PM EST
Filing Type: 6-K
Importance Score:
8
ACB
Feb 04, 2026, 7:27 AM EST
Filing Type: 6-K
Importance Score:
8
ACB
Feb 04, 2026, 7:05 AM EST
Filing Type: 6-K
Importance Score:
8
ACB
Jan 14, 2026, 7:22 AM EST
Filing Type: 6-K
Importance Score:
7